Skip to content

AJAGA: what changed

Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.

What changed

AJAGA

BE 0860.473.736
NACE 47.730, Retail sale of pharmaceutical products
financial year 2024 against 2025filed annual accounts (NBB)
Net result for the year
-€1,776
2024 · -€4,228+€2,452
Equity
€9,363
2024 · €11,140-€1,776
Cash
€6,048
2024 · €16,822-€10,774
Balance sheet total
€21,992
2024 · €17,168+€4,824

Largest movements

2024 to 2025
Assets
  • Receivables within one year +€15,598

    up €15,598 (+4511.0%), from €346 to €15,944

    of which Trade receivables: +€15,000

  • Cash -€10,774

    down €10,774 (-64.0%), from €16,822 to €6,048

    mainly Receivables within one year (-€15,598) and Accrued charges and deferred income (-€4,000)

Equity and liabilities
  • Other debts +€8,495

    up €8,495 (+474.2%), from €1,791 to €10,286

  • Accrued charges and deferred income -€4,000

    no longer reported in 2025 (was €4,000)

  • Trade debts +€2,106

    up €2,106 (+888.9%), from €237 to €2,343

  • Profit (loss) carried forward -€1,776

    down €1,776 (-22.0%), from -€8,080 to -€9,857

Income statement
  • Gross operating margin +€2,506

    up €2,506 (+69.3%), from -€3,614 to -€1,109

  • Financial charges +€40

    up €40 (+39.8%), from €100 to €140

From the 2024 result to the 2025 result

effect on the result

Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.

Result 2024 -€4,228
Gross operating margin +€2,506
Other operating charges -€14
Financial charges -€40
Result 2025 -€1,776

Cash bridge derived

cash 2024 to 2025

Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.

From operations -€10,774
Investment €0
Financing €0
Cash 2024 €16,822
Net result for the year -€1,776
Receivables within one year -€15,598
Trade debts +€2,106
Other debts +€8,495
Accrued charges and deferred income -€4,000
Cash 2025 €6,048
Every line side by side 26 lines
Line Code 2024 2025 Change %
Total assets 20/58 €17,168 €21,992 +€4,824 +28.1%
Current assets 29/58 €17,168 €21,992 +€4,824 +28.1%
Amounts receivable within one year 40/41 €346 €15,944 +€15,598 +4511.0%
Trade receivables 40 - €15,000 +€15,000
Other amounts receivable 41 €346 €944 +€598 +173.0%
Cash at bank and in hand 54/58 €16,822 €6,048 -€10,774 -64.0%
Total equity and liabilities 10/49 €17,168 €21,992 +€4,824 +28.1%
Equity 10/15 €11,140 €9,363 -€1,776 -15.9%
Contributions 10/11 €18,600 €18,600 = 0.0%
Reserves 13 €620 €620 = 0.0%
Distributable reserves 133 €620 €620 = 0.0%
Profit (loss) carried forward 14 -€8,080 -€9,857 -€1,776 -22.0%
Amounts payable 17/49 €6,028 €12,628 +€6,600 +109.5%
Amounts payable within one year 42/48 €2,028 €12,628 +€10,600 +522.6%
Trade debts 44 €237 €2,343 +€2,106 +888.9%
Suppliers 440/4 €237 €2,343 +€2,106 +888.9%
Other amounts payable 47/48 €1,791 €10,286 +€8,495 +474.2%
Accrued charges and deferred income 492/3 €4,000 - -€4,000
Other operating charges 640/8 €513 €528 +€14 +2.8%
Gross operating margin 9900 -€3,614 -€1,109 +€2,506 +69.3%
Operating profit (loss) 9901 -€4,128 -€1,636 +€2,492 +60.4%
Financial charges 65/66B €100 €140 +€40 +39.8%
Recurring financial charges 65 €100 €140 +€40 +39.8%
Profit (loss) for the period before taxes 9903 -€4,228 -€1,776 +€2,452 +58.0%
Profit (loss) for the period 9904 -€4,228 -€1,776 +€2,452 +58.0%
Profit (loss) for the period to be appropriated 9905 -€4,228 -€1,776 +€2,452 +58.0%

Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 11 October 2026 via checked.be.